CompletedNot Applicable

Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage

United States107 participantsStarted 2017-09-17

Plain-language summary

The purpose of this study is to evaluate the safety and effectiveness of the Jada System in the control and reduction of primary postpartum hemorrhage.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult Female, 18 years of age or older at time of consent.
✓. Able to understand and provide informed consent to participate in the study.
✓. Diagnosis of PPH with suspected atony within 24 hours after vaginal or c-section delivery.
✓. EBL, to be determined when investigator is ready to have Jada peel pack opened: a) vaginal delivery: 500 - 1500 ml EBL or b) c-section delivery: 1000 - 1500 ml EBL.
✓. Failed first-line intervention of uterotonics and uterine massage/bimanual compression to stop bleeding. Note: Uterotonic administration may continue concomitant with and post Jada use.

Exclusion criteria

✕. EBL \> 1500 ml, to be determined when investigator is ready to have the Jada peel pack opened.
✕. Delivery at a gestational age \< 34 weeks.
✕. For C-sections: Cervix \< 3 cm dilated before Jada use.
✕. PPH that the investigator determines to require more aggressive treatment, including any of the following: a) hysterectomy, b) b-lynch suture, c) uterine artery embolization or ligation, d) hypogastric ligation.
✕. Known uterine anomaly.
✕. Ongoing intrauterine pregnancy.
✕. Placenta abnormality including any of the following: a) known placenta accreta, b) retained placenta with known risk factors for placenta accreta (e.g. history of prior uterine surgery, including prior c-section and placenta previa), c) retained placenta without easy manual removal.
✕. Known uterine rupture.

What they're measuring

Efficacy: Rate of Participants With Cessation of Uterine Hemorrhaging

Timeframe: 24 hrs

Safety: Incidence (i.e., Rate or Number of Participants), Severity and Seriousness of Device-related Adverse Events Experienced by Participants

Timeframe: 6 weeks

Trial details

NCT IDNCT02883673

SponsorAlydia Health

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-01-26

Results submitted2021-04-29

View on ClinicalTrials.gov More Postpartum Hemorrhage trials